Document Detail


Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.
MedLine Citation:
PMID:  23041958     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: This review aims to address the temporal sequencing of involvement of amyloid-beta (Aβ) and tau in the pathogenesis of Alzheimer's disease and reconcile apparently conflicting neuropathologic and biomarker data.
RECENT FINDINGS: Although neuropathologic studies show that limbic system tau disease occurs ubiquitously in middle-aged individuals before the appearance of amyloid plaques, biomarker studies in living individuals suggest that Aβ disease is the initiating event in Alzheimer's disease and precedes cerebrospinal fluid tau changes. Evidence from neuropathologic, biomarker, genetic and cellular/mouse studies shows that tau accumulation in limbic regions occurs slowly with age and does not induce widespread neurodegeneration, but that Aβ interacts with tau in some way to accelerate neurofibrillary disease and induce neurodegeneration.
SUMMARY: Aβ aggregation is the key initial trigger of Alzheimer's disease pathologic changes and interacts with tau to exacerbate age-related tauopathy and induce neurodegeneration.
Authors:
Erik S Musiek; David M Holtzman
Related Documents :
8521688 - Nutritional anemias in infancy.
18474278 - Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies.
8548418 - Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb a...
15828898 - Challenges in the therapy of secondary hyperparathyroidism.
18638988 - Suspected mptp-induced parkinsonism.
23761098 - Erythrocyte sedimentation rate is a predictor of renal and overall sle disease activity.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current opinion in neurology     Volume:  25     ISSN:  1473-6551     ISO Abbreviation:  Curr. Opin. Neurol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-19     Completed Date:  2013-05-03     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  9319162     Medline TA:  Curr Opin Neurol     Country:  England    
Other Details:
Languages:  eng     Pagination:  715-20     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alzheimer Disease* / cerebrospinal fluid,  metabolism,  pathology
Amyloid beta-Peptides* / cerebrospinal fluid,  metabolism
Biological Markers / cerebrospinal fluid
Brain* / metabolism,  pathology
Disease Progression
Humans
Neurofibrillary Tangles / metabolism,  pathology
Plaque, Amyloid / metabolism,  pathology
Time Factors
tau Proteins* / cerebrospinal fluid,  metabolism
Grant Support
ID/Acronym/Agency:
K08 NS079405/NS/NINDS NIH HHS; K08NS07940501/NS/NINDS NIH HHS; P01 NS074969/NS/NINDS NIH HHS; P01NS074969/NS/NINDS NIH HHS; P30 NS057105/NS/NINDS NIH HHS; P30NS057105/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Biological Markers; 0/MAPT protein, human; 0/tau Proteins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotem...
Next Document:  Facilitating implementation of the translational research pipeline in neurological rehabilitation.